Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-proliferative combination therapy comprising satraplatin or JM118 and a taxane

A taxane and docetaxel technology, which can be used in anti-tumor drugs, drug combinations, active ingredients of heavy metal compounds, etc., can solve problems such as no implied therapeutic application

Inactive Publication Date: 2008-03-05
GPC BIOTECH AG
View PDF32 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, only gastric cell lines were analyzed in this study
And not all tested cell lines showed the same effect, the report does not imply therapeutic applications of its findings

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-proliferative combination therapy comprising satraplatin or JM118 and a taxane
  • Anti-proliferative combination therapy comprising satraplatin or JM118 and a taxane
  • Anti-proliferative combination therapy comprising satraplatin or JM118 and a taxane

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0289] The term "preparation of [the first] pharmaceutical composition" refers to any step or method performed or required in the manufacture of a pharmaceutical composition that is conveniently administered to a patient or individual in need thereof. The steps or methods include the preparation of the pharmaceutical composition, formulation of the pharmaceutical composition into a formulation, packaging of the pharmaceutical composition and other steps performed before the pharmaceutical composition is delivered, sought or provided to a pharmacist, doctor or nurse. It also includes methods and procedures performed by a pharmacist, physician or nurse prior to administration of the pharmaceutical composition. For example, the above-mentioned methods and steps performed by a pharmacist, doctor or nurse include dissolving the pharmaceutical composition in a suitable solvent for administration, such as injection; Administering or other steps permitting administration of the pharma...

example 1

[0328] Example 1. The effectiveness of satraplatin and its metabolites in cisplatin-resistant tumor cells

[0329] The inventors have observed the surprising result that the platinum-based compounds of the invention can be used to inhibit or kill tumor cells resistant to other platinum compounds such as cisplatin.

[0330] The A129 cp80 cell line (obtained by Tito Foio, NIH; BiochemPharmacol52, 1855) produced by ovarian tumor A2780 is highly resistant to cisplatin (in individual experiments, the relative resistance ranges between 80-106 times), but to Treatment with JM216, JM118 and JM383 remained susceptible (relative tolerability ranged between 0.19-2.59 fold in individual experiments (Table 1)). The parent non-variant cell line A129 was used as a control.

[0331] 1,000-5,000 cells per well were exposed to various concentrations of test compounds for 48 hours in order to calculate the IC50 values ​​shown in Table 1. Cytotoxicity was measured using the SRB method accordi...

example 2

[0335] Example 2. Synergy between platinum-based compounds and docetaxel

[0336] The inventors have observed the surprising result that a combination of platinum-based compounds, particularly satraplatin and JM118 and docetaxel, acts synergistically when sequentially exposed or contacted to cancer cells or tumor cells.

[0337] The prostate adenocarcinoma cell line PC-3 (ATCC accession number: CRL-1435; Invest Urol (1979) 17, 16; Cytogenet Cell Genet (1993) 62, 183) was used. PC-3 cells were obtained from non-confluent plates and seeded in 96-well plates at a density of 2,000 cells per well. At 37°C, 5% CO 2 The cells were cultured in F-12K medium supplemented with 10% FCS and 1% Pen / Strep under the condition of . Twenty-four hours after addition to the plate, cells were exposed to a range of concentrations of individual compounds and incubated for 48 hours. Cytotoxicity was then measured using the SRB method according to Shekan et al. (Example 1; J Natl Cancer Inst (199...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention describes a method for preventing and / or treating cancer or tumors, especially combination therapy, method, composition and pharmaceutical packaging including taxane and certain platinum-based chemotherapeutic agent.

Description

[0001] The present invention relates to a method for preventing and / or treating cancer or tumor, in particular to a combined therapy, method, composition and pharmaceutical packaging comprising taxane and certain platinum-based chemotherapeutic agents. Background of the invention [0002] Platinum compounds are among the most active chemotherapeutic agents available for the treatment of a variety of cancers and tumors. The use of some of these compounds, such as cisplatin, is limited by toxicity and tolerability. To overcome these problems, efforts have been made to discover new platinum compounds that do not share some of the properties of cisplatin. One compound that has been identified is satraplatin (JM216), a platinum (Pt) IV complex. Saplatin was chosen for clinical studies because of several favorable properties: (a) high cytotoxic activity in vitro against several solid tumor cell lines, including cisplatin-resistant cell lines; (b) In vivo oral antitumor activity in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/282A61K31/337A61P35/00
CPCA61K31/282A61K31/337A61P35/00A61K2300/00
Inventor 卡杰·沃席高斯基-巴特斯海曼苏·沙莫林·卡利吉瑞
Owner GPC BIOTECH AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com